东北制药(000597) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 1,947,277,598.78, a slight increase of 0.36% compared to CNY 1,940,260,731.63 in the same period last year[5]. - Net profit attributable to shareholders decreased by 36.98% to CNY 36,321,572.23 from CNY 57,633,861.05 year-on-year[5]. - Total operating revenue for the current period reached ¥1,947,277,598.78, a slight increase from ¥1,940,260,731.63 in the previous period, reflecting a growth of approximately 0.09%[21]. - Net profit for the current period was ¥35,371,414.93, down from ¥59,781,000.10 in the previous period, representing a decline of approximately 40.19%[22]. - The total comprehensive income for the current period was ¥35,312,945.96, down from ¥59,847,129.06 in the previous period, indicating a decrease of approximately 41.00%[23]. Cash Flow - The net cash flow from operating activities was negative at CNY -30,857,306.06, a decline of 132.52% compared to CNY 94,887,495.36 in the previous year[5]. - Cash generated from operating activities was ¥1,512,950,908.83, a decrease from ¥1,698,161,792.76 in the previous period, indicating a decline of about 10.92%[25]. - The net cash flow from operating activities was -30,857,306.06, a decrease from 94,887,495.36 in the previous period[26]. - Cash inflow from financing activities totaled 3,253,729,501.82, compared to 2,168,604,450.25 previously, indicating a significant increase[26]. - Cash outflow for financing activities was 3,317,380,209.04, compared to 1,967,909,321.94 previously, reflecting increased financial obligations[26]. Assets and Liabilities - Total assets decreased by 5.78% to CNY 13,611,193,970.86 from CNY 14,446,181,851.25 at the end of the previous year[5]. - Total current assets amount to 7,941,156,174.05 RMB, down from 8,646,485,795.58 RMB[18]. - Total non-current assets amount to 5,670,037,796.81 RMB, down from 5,799,696,055.67 RMB[18]. - Total liabilities decreased to ¥8,006,283,075.57 from ¥8,876,538,951.68, a reduction of about 9.78%[19]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 60,559[16]. - Jiangxi Fangda Steel holds 31.01% of shares, totaling 443,231,442 shares, with 285,062,211 shares pledged[16]. - Liaoning Fangda Group holds 23.03% of shares, totaling 329,068,713 shares, with no shares pledged[16]. Research and Development - R&D expenses increased by 88% to CNY 32,000,000 compared to the same period last year, indicating a significant investment in new product development[9]. - Research and development expenses increased to ¥31,999,540.39 from ¥17,035,942.04, marking an increase of approximately 88.50%[22]. Other Financial Metrics - The weighted average return on equity fell to 0.68% from 1.15% year-on-year, reflecting a decline in profitability[5]. - Earnings per share (basic and diluted) decreased to ¥0.025 from ¥0.040, reflecting a reduction of 37.50%[23]. - The company reported a net loss from credit impairment of ¥5,872,091.65, compared to a gain of ¥257,502.93 in the previous period[22]. - The company recorded a total of CNY 16,414,574.75 in non-recurring gains, primarily from government subsidies and debt restructuring[6]. Donations and Social Responsibility - The company donated 10 million RMB to earthquake relief efforts in Tibet[17].